The head of the US Food and Drug Administration (FDA) is considering using the agency’s powers to bring more price competition to the market for generic drugs, targeting high-priced products by prioritizing the approval of additional competing treatments.
FDA Commissioner Scott Gottlieb said in an interview on Monday that the agency is looking at how to push applications to the front of the line in cases where there are fewer than three competing generic manufacturers.
The policy would target cases where there are few or no competing versions of drugs, which has led to high prices in some situations.
In one now-infamous case, Turing Pharmaceuticals AG, then led by Martin Shkreli, bought the rights to sell a decades-old anti-infective drug called Daraprim and raised the price from US$13.50 to US$750 per pill.
Valeant Pharmaceuticals International Inc has likewise benefited from older drugs with limited competition, such as two treatments for the rare condition Wilson’s Disease. Valeant bought the treatments and raised their prices by about 30-fold.
Adding generic competitors would mean lower prices, Gottlieb said, adding that the goal is to have three manufacturers of every generic version of a drug.
That is the point at which prices start to fall significantly, he said.
“We know the most significant savings to consumers comes when there are three generics on the market,” Gottlieb said in a telephone interview.
US President Donald Trump has said he wants to address the issue of high US pharmaceutical prices, and drug executives last week said they expected the administration to act soon.
The first generic drug that hits the market will “only slightly lower” the price compared to the brand version, an FDA analysis said.
A second generic competitor approved would slash the price to almost half that of the brand version, while subsequent approvals would drop the cost to 20 percent of the brand version, it added.
The action on generic drugs would be a shift from the agency’s current stance; the FDA prioritizes applications for the first company to apply for a generic version of a brand-name product.
The agency has not typically considered drug costs as a major policy and is barred from taking them into account when deciding whether to approve a new drug.
The move is one of several actions Gottlieb said he plans to take to address drug costs.
The agency is also looking at a plan to eliminate within a year the backlog of 2,640 generic drug applications, Gottlieb said.
Other ideas Gottlieb has referenced include looking into ways to thwart brand-name drugmakers from using programs to restrict distribution of their products to keep generic drug manufacturers from accessing enough product for testing, which he said can require as many as 3,000 pills.
“Getting access to 3,000 tablets can be hard unless the branded companies are going to facilitate the ability of the generic companies to get the drug,” Gottlieb said. “They can’t just go into the market and buy it readily.”
The FDA is also looking into whether it can publish a list of the 180 brand-name drugs that no longer have patent protection and still do not face any generic competition, 150 of which the agency has never received an application from a generic drugmaker to review.
Publishing the list “might create a more compelling business opportunity,” Gottlieb said.
Many of these ideas are to be discussed at a public hearing the FDA plans to hold in the next several months to discuss ways to facilitate generic drug competition, Gottlieb said.
He has also talked about finding ways to speed approvals of generics that copy complex medications, including allergy shots or asthma inhalers such as Mylan NV’s EpiPen or GlaxoSmithKline PLC’s Advair.
The products create an additional complication, because they combine a drug with an administration device.
Gottlieb said he expects the agency to release “a whole series” of documents to guide the industry on the issue, since generic drug manufacturers can run into trouble showing that their versions of the drug and device are equivalent.
NOTABLE SHIFT: By 2030, 50% of all laptops would be assembled in Southeast Asia, while Taiwan would still mostly focus on research and development, a report said Global laptop and desktop computer supply chains are expected to shift significantly away from China in the next 10 years, a Market Intelligence & Consulting Institute (MIC, 產業情報研究所) report said. By 2030, only 40 percent of global laptop production would remain in China, said the report, which was released on Thursday. “The reshuffling of the global supply chain will be one of the most important trends in the next 10 years,” the institute said in the report. “In the long run, key component makers will follow laptop assemblers in moving out of China.” The Taipei-based institute predicted most key component makers
NO VIRUS BLUES: A SEMI Taiwan official said that the virus does not slow down the global semiconductor industry’s investment in manufacturing equipment The production value of the nation’s semiconductor industry is expected to grow 16.7 percent this year from last year, outpacing the global industry’s 3.3 percent growth, industry association SEMI said yesterday. That would help Taiwan safeguard its second spot in the global semiconductor market with a production value of more than NT$3 trillion (US$102.73 billion), SEMI Taiwan president Terry Tsao (曹世綸) told a media briefing in Taipei for the Semicon Taiwan trade show beginning today. The global semiconductor industry’s production value is expected to increase to US$426 billion this year, SEMI said. In terms of semiconductor equipment investment, equipment billings from Taiwanese firms
Intel Corp has received licenses from US authorities to continue supplying certain products to Huawei Technologies Co (華為), a company spokesman said yesterday. Washington has been pushing governments around to world to squeeze out Huawei, saying that the telecom giant would hand data to Beijing for espionage. From Monday last week, new curbs have barred US companies from supplying or servicing Huawei. This week, the state-backed China Securities Journal reported that Intel had received permission to supply Huawei. China’s Semiconductor Manufacturing International Corp (SMIC, 中芯國際), which uses US-origin equipment to make chips for Huawei and other companies, last week confirmed that it had sought
Merck Group Taiwan yesterday said that it plans to invest substantially on expanding its fab in Kaohsiung’s Lujhu District (路竹) to better serve its local customers, including Taiwan Semiconductor Manufacturing Co (TSMC, 台積電). The company said it plans to expand its production space by 50 percent in the next five years and its workforce by about 40 percent, Merck Group Taiwan managing director Dick Hsieh (謝志宏) told a media briefing in Taipei. Hsieh declined to disclose investment details, but said that the latest investment would exceed the total amount Merck has invested in Taiwan over the past few years. Those investments would be